Moingeon Ph
Aventis Pasteur, Département de Recherche et Développement, Campus Mérieux, 1541 Avenue Marcel Mérieux, F 69280, Marcy L'Etoile, France.
Ann Pharm Fr. 2002 Jul;60(4):253-9.
Our strategy is to develop multivalent recombinant vaccines capable of eliciting broad immune responses in patients with malignant melanoma or colorectal cancer. Our current focus is on the induction of tumor-specific T cell responses using a prime-boost immunization schedule with a unique vector system derived from the canarypox virus called ALVAC, in which we incorporate genes encoding Tumor Associated Antigens (TAAs). A series of phase I/II clinical studies evaluating ALVAC recombinants carrying either the CEA, p53, MAGE1 or MAGE3 genes, administered through the subcutaneous, intradermal or intravenous routes, has shown that this approach is safe and can induce tumor-specific antibody or T cell responses in at least some of the patients. Based on these encouraging results, future candidate vaccines will likely target multiple tumor-associated antigens, using several antigen presentation platforms associated in prime-boost immunization regimens.
我们的策略是开发能够在恶性黑色素瘤或结直肠癌患者中引发广泛免疫反应的多价重组疫苗。我们目前的重点是使用一种初免-加强免疫方案来诱导肿瘤特异性T细胞反应，该方案采用一种源自金丝雀痘病毒的独特载体系统，称为ALVAC，我们在其中整合了编码肿瘤相关抗原（TAAs）的基因。一系列评估通过皮下、皮内或静脉途径给药的携带CEA、p53、MAGE1或MAGE3基因的ALVAC重组体的I/II期临床研究表明，这种方法是安全的，并且至少在一些患者中可以诱导肿瘤特异性抗体或T细胞反应。基于这些令人鼓舞的结果，未来的候选疫苗可能会使用初免-加强免疫方案中相关的几种抗原呈递平台来靶向多种肿瘤相关抗原。
